Home›Stock Screener›Anthem Biosciences›Intrinsic Value

Anthem Biosciences Intrinsic Value

Anthem Biosciences intrinsic value. Anthem Biosciences (ANTHEM) median intrinsic value is ₹427.14 from 9 valuation models (range ₹285–₹989), vs current price ₹951.05 — -55.1% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse Anthem Biosciences shareholding analysis to track promoter, FII and institutional holdings.

Market Price (CMP)
₹951.05
Primary Intrinsic Value
₹285.31
Market Cap
₹106.5K Cr
-55.1% Downside
Median Value
₹427.14
Value Range
₹285 - ₹989
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%

ANTHEM Valuation Methods Summary — DCF, Graham Number & P/E

Anthem Biosciences intrinsic value across 9 models vs current price ₹951.05 — upside/downside and value range per method. For current market price and key ratios, visit Anthem Biosciences share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹285.31 ₹228.25 - ₹342.37 -70.0% EPS: ₹12.36, Sector P/E: 22x
Book Value Method asset ₹430.36 ₹387.32 - ₹473.40 -54.7% Book Value/Share: ₹215.18, P/B: 2.0x
Revenue Multiple Method revenue ₹427.14 ₹384.43 - ₹469.85 -55.1% Revenue/Share: ₹213.57, P/S: 2.0x
EBITDA Multiple Method earnings ₹950.00 ₹855.00 - ₹1045.00 -0.1% EBITDA: ₹1064.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹432.02 ₹345.62 - ₹518.42 -54.6% CF Growth: 10.7%, Discount: 15%
PEG Ratio Method growth ₹285.31 ₹256.78 - ₹313.84 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹285.31 ₹256.78 - ₹313.84 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹988.57 ₹889.71 - ₹1087.43 +3.9% ROE: 28.7%, P/E Multiple: 16x
Graham Defensive Method conservative ₹285.31 ₹256.78 - ₹313.84 -70.0% EPS: ₹12.36, BVPS: ₹215.18
Method Types: Earnings Asset DCF Growth Dividend Conservative

ANTHEM Intrinsic Value vs Market Price — All Valuation Models

Anthem Biosciences fair value range ₹285–₹989 vs current market price ₹951.05 across 9 valuation models. Browse ANTHEM annual financials for revenue, profit, balance sheet and cash flow data.

ANTHEM Intrinsic Value Analysis — Undervalued or Overvalued?

Anthem Biosciences median intrinsic value ₹427.14, current price ₹951.05 — Trading Above Calculated Value by 55.1%, margin of safety -100.0%.

What is the intrinsic value of ANTHEM?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Anthem Biosciences (ANTHEM) is ₹427.14 (median value). With the current market price of ₹951.05, this represents a -55.1% variance from our estimated fair value.

The valuation range spans from ₹285.31 to ₹988.57, indicating ₹285.31 - ₹988.57.

Is ANTHEM undervalued or overvalued?

Based on our multi-method analysis, Anthem Biosciences (ANTHEM) appears to be trading above calculated value by approximately 55.1%.

ANTHEM Financial Health — Key Ratios vs Industry Benchmarks

Anthem Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Current Ratio 24.12 Industry Standard: 2.0+ Above 2.0 Measures short-term liquidity capacity
Return on Equity 28.7% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 40.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.85x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

ANTHEM Cash Flow Quality — Operating & Free Cash Flow

Anthem Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2025 ₹418 Cr ₹342 Cr Positive Free Cash Flow 8/10
March 2024 ₹140 Cr ₹29 Cr Positive Free Cash Flow 7/10
March 2023 ₹306 Cr ₹118 Cr Positive Free Cash Flow 7/10
March 2022 ₹333 Cr ₹231 Cr Positive Free Cash Flow 8/10
March 2021 ₹278 Cr ₹180 Cr Positive Free Cash Flow 8/10